Glaukos (NYSE: GKOS) COO sells shares after exercising options
Rhea-AI Filing Summary
Glaukos Corporation’s President and COO, Joseph E. Gilliam, reported option exercises and related share sales. On January 22, 2026, he exercised stock options for 10,498 shares of common stock at an exercise price of $55.18 per share, from options originally granted on March 24, 2022 that were tied to multi-year performance goals and operational targets.
On the same date, he sold blocks of Glaukos common stock totaling 2,406, 3,100, 1,798 and 3,194 shares at weighted average prices of $126.10, $127.03, $128.07 and $129.28, respectively. These transactions, as well as the option exercises, were carried out under a Rule 10b5-1 trading plan adopted on June 11, 2025. After these transactions, Gilliam beneficially owned 92,366 shares of common stock, which includes 62,605 restricted stock units that have not yet vested or been delivered.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 7,398 | $55.18 | $408K |
| Exercise | Stock Option (Right to Buy) | 3,100 | $55.18 | $171K |
| Exercise | Common Stock | 10,498 | $55.18 | $579K |
| Sale | Common Stock | 2,406 | $126.10 | $303K |
| Sale | Common Stock | 3,100 | $127.03 | $394K |
| Sale | Common Stock | 1,798 | $128.07 | $230K |
| Sale | Common Stock | 3,194 | $129.28 | $413K |
Footnotes (1)
- Includes 62,605 restricted stock units that have not yet vested or been delivered to the Reporting Person. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2025. This transaction was executed in multiple trades at prices ranging from $125.56 to $126.55. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $126.62 to $127.58. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $127.83 to $128.77. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $128.98 to $129.81. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. The option exercises reported in this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2025. Represents a portion of an option to purchase shares of common stock previously granted by the Issuer on March 24, 2022, the vesting of which was subject to the Issuer's achievement of certain pre-determined operational targets over a multi-year performance period. Represents a portion of an option to purchase shares of common stock previously granted by the Issuer to the Reporting Person on March 24, 2022 in connection with his promotion to President and Chief Operating Officer, the vesting of which was subject to the Issuer's achievement of certain multi-year performance goals.
FAQ
What insider transaction did Glaukos (GKOS) report for its President & COO?
Was the Glaukos (GKOS) insider trading activity under a 10b5-1 plan?
What stock options did the Glaukos (GKOS) President & COO exercise?